Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes
Conclusion: Dulaglutide is a once-weekly GLP-1 RA approved for the treatment of T2DM that has shown similar efficacy to other agents in this class. Keywords: GLP-1 RA, glucagon-like peptide-1 receptor agonist, incretin mimetic, type 2 diabetes mellitus therapy
Source: Core Evidence - Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Fortamet | Gastroenterology | Health | Heart | Incretin Therapy | Metformin | Nutrition | Pancreatitis | Sports Medicine | Weight Loss